Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nebius Group NV (NBIS) vs Twist Bioscience Corp (TWST) Price & Performance

Nebius Group NVTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Nebius Group NV vs Twist Bioscience Corp — how do they compare? Nebius Group NV trades at $233.24 (market cap $49.06B), while Twist Bioscience Corp trades at $122.44 (market cap $7.72B). The key difference: Nebius Group NV is far larger — about 6.4× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.

NBISTWST
Market Cap
$49.06B$7.72B
Sector
TechnologyHealth
52-Week High
$286.69$124.88
52-Week Low
$64.06$24.16
Enterprise Value
$49.26B$7.65B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nebius Group NV

NBIS stock surged 23.65% to $227.66 on strong Q2 2026 earnings that beat expectations, extending its AI cloud rally. The company shows explosive revenue growth with 2026 projections indicating $878 million revenue and $817 million net income, though current valuations remain elevated with a P/E of 74.61. Technical indicators show bearish momentum despite the recent price surge, with support at $190 and resistance at $196.

The outlook remains positive given strong analyst consensus (89% buy ratings) and a $248.73 price target, but risks include Michael Burry's short position, execution challenges in capacity expansion, and premium valuation multiples that leave little room for error in meeting growth expectations.

Twist Bioscience Corp

TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.

The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nebius Group NV

Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.

Read more on NBIS

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST